Zoetis Inc (ZTS) Falls 3.49% for January 13

Equities Staff |

One of the S&P 500’s big losers for Wednesday January 13 was Zoetis Inc (ZTS). The company’s stock fell 3.49% to $43.40 on volume of 3.1 million shares.

The stock opened the day at 45.25 and traded between a low of $43.03 and a high of $45.33. The stock finished the day down $1.57 per share. Zoetis Inc has an average daily volume of 3.65 million and a total float of 497.92 million shares. The 50-day SMA for Zoetis Inc is $46.44 and its 200-day SMA is $46.32. The high for the stock over the last 52 weeks is $55.38 and the low is $37.73.

Zoetis Inc discovers, develops, manufactures & commercializes animal health medicines & vaccines for livestock & companion animals. Its products include anti-infectives, vaccines, parasiticides, medicated feed additives & other pharmaceutical products.

Zoetis Inc is centered in Florham Park, NJ, and has 10,000 employees. Today’s trading day leaves the company with a market cap of $21.61 billion. The company has a P/S ratio of n/a, P/B ratio of 17.57, and a -198.2.

For a complete fundamental analysis analysis of Zoetis Inc, check out Equities.com’s Stock Valuation Analysis report for ZTS. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Cavitation Techs Inc

Cavitation Technologies Inc engineers and designs Nano technology based systems that have potential applications in industrial liquid processing.

Private Markets

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…


Autonomous security robots providing advanced detection capabilities at $7 per hour - aiming to define the future of security. Help #StopTheViolence.